Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Contributed by: PR Newswire

Tags

HANSA-BIOPHARMA-SERB

More Like This

Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA

SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million

SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update

Hansa Biopharma Year-end report January-December 2023

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results